ID: ALA3740371

Max Phase: Preclinical

Molecular Formula: C20H17FN4O4

Molecular Weight: 396.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(c1ccccc1F)N1CCN(C(=O)c2c[nH]c3ccc([N+](=O)[O-])cc23)CC1

Standard InChI:  InChI=1S/C20H17FN4O4/c21-17-4-2-1-3-14(17)19(26)23-7-9-24(10-8-23)20(27)16-12-22-18-6-5-13(25(28)29)11-15(16)18/h1-6,11-12,22H,7-10H2

Standard InChI Key:  XTFOZUNDQSDBPD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.38

Molecular Weight (Monoisotopic): 396.1234

AlogP: 2.81

#Rotatable Bonds: 3

Polar Surface Area: 99.55

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.12

CX Basic pKa:

CX LogP: 2.38

CX LogD: 2.38

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.54

Np Likeness Score: -1.50

References

1. Papaneophytou C, Alexiou P, Papakyriakou A, Ntougkos E, Tsiliouka K, Maranti A, Liepouri F, Strongilos A, Mettou A, Couladouros E, Eliopoulos E, Douni E, Kollias G, Kontopidis G.  (2015)  Synthesis and biological evaluation of potential small moleculeinhibitors of tumor necrosis factor,  6  (6): [10.1039/C5MD00023H]

2. Rinotas V,Papakyriakou A,Violitzi F,Papaneophytou C,Ouzouni MD,Alexiou P,Strongilos A,Couladouros E,Kontopidis G,Eliopoulos E,Douni E.  (2020)  Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.,  63  (20.0): [PMID:32955874] [10.1021/acs.jmedchem.0c01316]

Source

Source(1):

• Scientific Literature